Intelence

Type: Product
Name: Intelence
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Most Patients Could Switch to Better-Tolerated Antiretroviral Regimens, Study Concludes

The study, published in PLOS ONE, looked at the treatment history and drug resistance profile of participants, as well as tropism testing for maraviroc (Selzentry, Celsentri) where possible (only available for 38% of people studied). The RATE drugs in ... [Published The Body PRO - Jul 22 2014]
First reported Jul 11 2014 - Updated Jul 11 2014 - 1 reports

Therapy with newer, safer antiretrovirals an option for the majority of HIV-positive patients

The majority of patients taking antiretroviral therapy (ART) that includes drugs associated with long-term side-effects may have the option of switching to a novel regimen that uses newer and safer anti-HIV drugs, according to Australian research published ... [Published Aidsmap - Jul 11 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Trevena Appoints Julie H. McHugh and Barbara Yanni to the Board of Directors

. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Julie H. McHugh, former president of Centocor and chief operating officer at ... [Published Wall Street Select - Jul 01 2014]
First reported Jun 26 2014 - Updated Jun 26 2014 - 1 reports

Pharmaceutical Spray Drying Market, 2014 - 2024

EXAMPLE HIGHLIGHTS1. Spray drying has been used extensively for APIs in the pharmaceutical industry; however, there are only a few examples of spray dried commercial drugs. These include Intelence, Kalydeco, Incivek, and Zortress.2. Specific to the pharmaceutical ... [Published MarketResearch.com - Jun 26 2014]

Quotes

...The study authors did caution, however, that "most of the regimens considered as 'viable' in this study have not been rigorously tested in clinical trials and might be regarded as unconventional." The authors concluded that randomized, controlled trials would be necessary to determine the advantages and disadvantages of switching stable patients...
...and are in need of new treatment options," said Paul Stoffels, MD, chief scientific officer, Johnson & Johnson and worldwide chairman, Janssen. "We hope this innovative donation programme is the first step in sparking further collaborative action across sub-Saharan Africa for children who are experiencing HIV treatment failure. Our vision is that these children receive the HIV treatment and care they need to stay healthy and grow to become healthy, productive young adults."

More Content

All (6) | News (5) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Most Patients Could Switch to Better-Tolerated ... [Published The Body PRO - Jul 22 2014]
Therapy with newer, safer antiretrovirals an op... [Published Aidsmap - Jul 11 2014]
Trevena Appoints Julie H. McHugh and Barbara Ya... [Published Wall Street Select - Jul 01 2014]
Pharmaceutical Spray Drying Market, 2014 - 2024 [Published MarketResearch.com - Jun 26 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Jun 26 2014]
Janssen launches first-of-its-kind paediatric H... [Published PharmaBiz - Dec 10 2013]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Jun 26 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.